Evaluation of Clinical Innovation: A Gray Zone in the Ethics of Modern Clinical Practice? by Patenaude, Johane et al.
Evaluation of Clinical Innovation: A Gray Zone in the Ethics
of Modern Clinical Practice?
Johane Patenaude, PhD
1, Andrew M. Grant, MB, ChB, MRCP, FRCPC, FACMI, DPhil
2,
Marianne Xhignesse, MD, MSc
3, Frédéric Leblanc, MSc
4, and Josiane Courteau, PhD
5
1Department of Surgery, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada;
2Collaborative
Research for Effective Diagnostics, Department of Biochemistry, Faculty of Medicine and Health Sciences, Université de Sherbrooke,
Sherbrooke, QC, Canada;
3Department of Family Medicine, Chaire Lucie et André Chagnon pour l’enseignement d’une approche intégrée
en prévention, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada;
4Faculty of Medicine and
Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada;
5Research Clinical Center, Centre hospitalier universitaire de
Sherbrooke, Sherbrooke, QC, Canada.
BACKGROUND: Various stakeholders can have differ-
ing opinions regarding ethical review when introducing
new procedures with patients.
OBJECTIVE: This pilot study examines the way in
which Research Ethics Boards (REBs; Institutional
Review Boards) and clinical biochemists (CBs; labora-
tory medicine specialists) differ in their interpretation of
what is research and what should be considered
common practice versus innovation versus experimen-
tation when introducing new procedures with patients.
It also explores whether these groups agree on who is
responsible for the ethical review of new procedures.
METHODS: A validated case scenario for the introduc-
tion of a new diagnostic test into clinical practice was
sent to CBs and REBs across Canada. Participants
were asked to determine whether the scenario consti-
tuted research; whether the test procedure should be
considered as experimental, innovative, or commonly
accepted care; and whether the project required ap-
proval by a REB and, if not, who should be responsible
for ethical review.
RESULTS: Results showed 81% of 37 CBs and 52% of
27 REBs identified the scenario as research. Responsi-
bility for ethical review was assigned to REBs by 44% of
REBs and 54% of CBs. Of all participants, 53%
classified the test procedure as ‘innovative’,8 %a s
‘experimental’, whereas 17% classified it as ‘commonly
accepted’.
CONCLUSIONS: This pilot study indicates a substantial
variation in the ethical assessment of innovation in
clinical care. This suggests the need to further elaborate
on the types of innovation in health care and categorize
the nature of the risks associated with each.
KEY WORDS: ethics; innovation; practice variation; decision making;
decision analysis; care giving.
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BACKGROUND
Current, evidence-based medicine is undergoing unprecedent-
ed development.
1,2 New diagnostic and therapeutic methods
resulting from biomedical research are being introduced into
practice at an increasing rate. These innovations are not with-
out risk and should not be permitted at the expense of ethical
values.
3,4 The challenge presented by the range of innovations
in the practice of medicine is to determine whether new tests
are acceptably sensitive and specific and whether new medica-
tions and procedures are acceptably safe and effective.
5
In Canada and many other countries, medical intervention
on human subjects deemed as “experimental care” requires
that a protocol be submitted to a REB.
6 This entity is equiv-
alent to those in many countries, such as the Institutional
Review Boards (IRB) in the USA, whose common mission is the
protection of research subjects. This level of control no longer
holds for procedures past the experimental stage. Thus,
“innovative care” that uses a clinical-practice procedure that
is beyond the experimental stage is not subject to review and
monitoring by a REB. Nonetheless, without a commonly ac-
cepted definition of “innovation”, the question persists as to
what should qualify in practice as experimental care.
The research literature and certain national policies on re-
search involving humans have examined definitions of exper-
imental care, innovative care, and standard care. A procedure
is classified under the concept of experimental care,
7,8 if it
involves an action whose clinical effectiveness has not been
recognized and it is not yet known whether it will produce the
benefits sought.
The concept of innovative care has been linked to several
definitions viewing it both as a dynamic and complex process.
Thus, its nature and degree can vary from 1 procedure to
another.
9,7 Still, other definitions place it on the continuum
between research and practice.
2,10,11 In Quebec,
12 innovative
care sits astride newly accepted and experimental procedures:
their efficacy has been demonstrated, but, for lack of ex-
perience, methods of application and precise indications for
use remain to be specified. This definition emerges from
Article 21 of the Civil Code of Québec, according to which
“Care considered by the ethics committee to be innovative care
required by the state of health of the person concerned does
not constitute an experiment”. The lack of precision of this
language has been criticized.
13 The less controversial concept
27of standard or commonly accepted care is applied to clinical
procedures whose clinical effectiveness, indications for use,
and protocols are well established.
The gray zone that divides experimental care in humans
from innovative care within clinical practice can give rise to
difficulties for Research Ethics Boards and health profes-
sionals called upon to distinguish one from the other; the
more so as biomedical research and the practice of medicine
often take place within a single institution, heightening the
possibility of confusion as to a procedure’s purpose.
14
Such confusion can result in variations among the opinions
of those responsible for classifying procedures. Classifying
experimental care as innovative, allows for administering
experimental procedures to patients without observing the
ethical and scientific norms for experiments on humans,
whereas classifying innovative care as experimental might
subject it to excessive ethical and scientific monitoring and
could considerably delay patients’ benefiting from clinical
advances.
These situations raise the questions: “At what point should
clinical applications be subject to the same standards for
protecting subjects as those required in research?” At what
point does modification of a standard technique constitute
more than a modification and become research? There is very
little research that has studied the extent of variation in
opinion between health professionals or REBs.
15,16 This pilot
study was designed therefore to investigate the extent and
nature of this variation. clinical biochemists (CBs) were
specifically chosen as the target health professional group for
this study as they are responsible for determining whether a
new diagnostic test should be introduced into the clinical
repertoire. They may have medical or scientific training. This
role has equivalence in many countries including that of a
laboratory medicine specialist in the USA.
OBJECTIVE
This pilot study examines the way in which REBs (Institutional
Review Boards) and CBs (laboratory medicine specialists) differ
in their interpretation of what is research and what should be
considered common practice versus innovation versus exper-
imentation when introducing new procedures with patients. It
also explores whether these groups agree on who is responsi-
ble for the ethical review of new procedures.
Methods
Demonstrating perceptible variation in criteria used to deter-
mine the status of a new practice presumes assessment of the
same project. To this end, a case scenario “Evaluation of the
Impact of Introducing BNP Analysis into Clinical Practice to
Diagnose Heart Failure” was devised. The case scenario was
based on a new practice of current interest and with consid-
erable variation between centers on policies of adoption.
17,18,19
It relates specifically to the development of a protocol for the
introduction of a diagnostic test aimed at enhancing clinical
effectiveness.
The test described in the case scenario (brain natriuretic
peptide or BNP) has been approved for clinical use by the FDA.
Its role in heart failure diagnosis has been shown to be very
promising but this has still to be fully established.
20,21 The
case scenario identifies 4 objectives: determine the analytical
performance in the local laboratory; determine guidelines for
optimal use; correlate the BNP test with other measures of
heart failure; and to evaluate the cost–benefit ratio. The test
would be made available without any change required in
normal practice. A comparison of practice data before and
after test introduction would be carried out to evaluate impact
on choice of other investigations; choice of treatment; length of
hospital stay; and overall costs. This case scenario was
developed to allow for targeting significant variation among
decision-makers classifying a procedure at the interface
between research on humans and clinical practice.
Three professional CBs and 2 REB members validated the
case scenario to ensure its credibility and realism. A self-
administered questionnaire consisting of 6 questions was de-
vised to gather participants evaluation regarding: (Question 1)
whether or not the case scenario project constituted a re-
search project (yes or no); (Question 3) how the procedure
(test) described in the case scenario should be classified
(for example, experimental, innovative, commonly accepted,
or other); (Question 5) whether or not they thought the project
required approval by a REB (yes or no); and if not, (Question 6)
who should be responsible for project review. Answers to the
closed questions (1, 3, 5, and 6) in the original questionnaire
are presented in Table 1. Open-ended questions 2 and 4 gave
access to the different explanations given for questions 1 and
3. The Fisher’s exact test was used to assess if the answers
differed between CBs and REBs.
Participants
The case scenario and questionnaire were transmitted by post
mail between May 2003 and February 2004 to 53 biomedical
REBs across Canada highly concerned by ethical issues of
clinical innovation in their institution and that had agreed to
take part in the study. The biomedical REBs were explicitly
Table 1. Comparison of Responses of CBs and REBs to the 4 Closed
Questions
CBs REBs P value
Number of participants 37 27
Question 1: In your view, does this
project constitute a research
project?
.0160
Yes 30 (81%) 14 (52%)
No 7 (19%) 13 (48%)
Question 3: In your view, how
should one describe the new
procedure that is the subject of
this project?
.0379
Experimental 3 (8%) 2 (7%)
Innovative 25 (68%) 9 (33%)
Commonly accepted 4 (11%) 7 (27%)
Other 5 (14%) 9 (33%)
Questions 5 and 6: In your view,
does this project require approval
by a REB? If not, who should be
responsible for project review?
.6131
Yes 20 (54%) 12 (44%)
No 17 (46%) 15 (56%)
Clinical Ethics Board 2 (5%) 2 (7%)
Other authority 8 (22%) 11 (41%)
Investigators themselves 7 (19%) 2 (7%)
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might normally come to their attention in the course of their
work and give it no special treatment. A further requirement
was that the ethical review handed down should represent the
review of the REB as a whole and not that of a single member
speaking as an individual. Responses were accepted until April
2004.
Duringthisperiod,thesamecasescenarioandquestionnaire
were also transmitted by e-mail to members of the Canadian
Society of Clinical Chemistry (CSCC), the Association des
médecins biochimistes du Québec (AMBQ), and the members
of the Société québécoise de biochimie clinique (SQBC).
Responses to the closed questions were analyzed quantita-
tively as percentages, presented in this study in table format.
Analysis of the open-ended questions was by mixed classifica-
tion using criteria identified in the scientific literature or
derived from the data themselves.
22,23
This project was approved by the REB of the Sherbrooke
University Hospital Center (Centre hospitalier universitaire de
Sherbrooke), in Sherbrooke, Quebec, Canada.
RESULTS
Twenty-seven biomedical REBs and 37 CBs in Canada partic-
ipated in this pilot study. Questionnaires were transmitted to
CB members of the Canadian Societies of Clinical Chemistry
(n=273) and to 53 Canadian biomedical REBs that had agreed
to take part in the study. Fourteen percent of CBs and 51% of
REBs participated. Table 1 presents the comparison of re-
sponses of CBs and REBs to the 4 closed questions.
Out of the participating CBs, 30 (81%) deemed the case sce-
nario to constitute research compared to 52% of REBs (p=
.0160). Sixty-eight percent of the CBs considered the procedure
as innovative compared to only 33% of the REBs. Only 8% of all
participants (REBs and CBs) considered the procedure to be
experimental, whereas 17% at the other end of the spectrum
categorized it as being part of commonly accepted care. The
REBs andCBsshowed a considerable divergence ofopinion with
regard to the classification of the biochemical test procedure
(p=.0379).
There was no consensus among either the REBs or the CBs
as to the authorities responsible for the ethical review of the
case scenario. Of all 64 participants in the study (27 REBs and
37 CBs), 44% of REBs and 54% of CBs assigned this re-
sponsibility wholly or partly to the REB, however, the differ-
ence is not statistically significant (p=.6131).
The REBs tended to classify the case scenario as a research
project and gave REBs ethical responsibility. CBs who desig-
nated REBs responsible did not necessarily view the case
scenario as constituting a research project, however, some of
them considered that REBs should oversee the introduction of
the test procedure. Indeed, according to them, innovation
associated with practice change may not be without risk.
DISCUSSION
This countrywide study brings to the forefront evidence of an
underestimated and generally poorly understood challenge,
namely, that of the ethical norms that need to be applied to the
spectrum of innovation in clinical practice. At a time when the
risks of health care are being widely announced,
24,3 little
attention is being paid to the different risks associated with
the continual drive to import new diagnostics or other
innovative procedures into clinical practice.
Both REBs and CBs were highly divided on whether the
case scenario constituted research on humans. Divergence in
this basic understanding could have important clinical impact
with risks of inappropriate medical decisions, prolongation of
institutional stay, and unneeded costs to the health system. All
of these issues have ethical implications.
About half (54%) of the CBs participating were likely to
consider that such a clinical project should be brought before
their REB before being implemented. The remainder would see
no need to notify their REB, which would mean that the latter
would be unaware that such a project was underway within
their own institutions. Of the CBs, 27% would either consider
other professional or hospital authorities responsible for
ethical review, whereas 19% would simply hold themselves
responsible.
Among participating REBs, approximately half would view
the project as research and thereby impose standard research
practice on clinicians. This finding is of interest given that few
respondent REBs (7%) considered the test procedure experi-
mental care. This gap could derive from the unclear distinction
between research “on” humans and research “involving”
humans and perhaps contribute to the fact that participating
REBs did not agree on the limits of their sphere of compe-
tence.
25 This is troubling, given the importance of the REBs’
decision-making role in many jurisdictions. The remaining
REBs, should they be consulted by clinicians, would refer
them to other professional or hospital authorities (38%) or not
refer them at all (3%). It may be supposed that participating
REBs (27%) and CBs (11%) who classified the test procedure
as commonly accepted care—a classification conferring ex-
emption from ethical and scientific review by a REB—would be
less likely, given their classification to consult colleagues or a
REB.
Other than a clear tendency to identify the test procedure
described in the case scenario as not being experimental care
(93%), no pronounced trend can be identified in the REBs’
classification of the procedure. In contrast to the REBs, a
majority of CBs (68%) classified the test procedure as innova-
tive care.
An effect of professional culture may account for the gap
between the opinions of the 2 groups surveyed. REBs’ criteria
reveal the importance assigned to scientific, public, and wide-
spread recognition. Conversely, CBs appear to view recognition
of this kind as only one of the aspects to consider and give
equal weight to criteria associated with clinical practice, which
is considerably influenced by experience and context, such as
other institutions’ recognition of the test procedure and the
professional and financial impacts of its implementation in
their own institution.
The important variation between CBs and REBs in our pilot
study addresses Agich’s deeper question about the legitimate
place of innovation in the clinical practice of medicine and
the ethical standards that should apply.
16 According to Agich,
the complex processes characteristic of clinical innovation
are often not reducible to a scientific protocol. They typically
involve intuition, experience, and an evolving knowledge about
the treatment and disease processes and the interaction be-
tween treatment and pathology. Whereas scientific knowledge
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required in a scientific protocol is often not attainable or not
useful in the early phases of development. He argues: “Given
the widespread acceptance of a regulatory ethics paradigm
(REP), bioethicists have not been inclined to examine closely
the actual processes by which clinical innovations are devel-
oped and the initial conditions prerequisite for the application
of the paradigm”. Agich highlights this important omission
because it has permitted the extension of a regulatory ethics
paradigm into the domain of clinical innovation without an
adequate assessment of the advantages and disadvantages of
such an expansion. For now, innovation in clinical practice
presents a moving target for the mandate of REBs.
It should be noted that REB participants in this survey may
not be representative of the whole community of biomedical
REBs in Canada. The findings we present in this study make
no claims to predictive value or statistical validity. Their
purpose is first and foremost to offer an analytical reflection
of the decisions and decision-making criteria used by partic-
ipating clinicians and REBs in reviewing a single clinical
project.
CONCLUSIONS
This pilot study shows significant variation in opinion among
participating REBs and CBs in determining whether a partic-
ular case scenario constitutes experimental, innovative, or
commonly accepted practice. Among REBs, the divergence is
especially noticeable. The odds of investigators getting 1
response or the other from a REB are roughly 50–50, effectively
the same as a coin toss. This situation can only affect REBs’
credibility for the worse.
Do these divergences entail a lower level of protection for
subjects? It is not the purpose of our study to engage this
question, but it ought to be addressed in the light of the
decision-making practices of those responsible for interpreting
and applying existing norms. Although it may be neither
realistic nor desirable to seek highly reduced variation between
CBs’ and REBs’ opinions, it is to be hoped that further criteria
will be defined to reduce this variation to reasonable levels.
This is all the more desirable given that, for a new test
procedure to be deemed reasonable, peers of those introducing
it must share that view of it.
26 The variation in REB response
suggests that there is an important need for further research
and education to align ethics approval policies. The concern of
the CBs regarding the scenario was that the test procedure
described (in its current state of innovation) was still associat-
ed with uncertainty as to its potential benefit or harm. This
was less evident to the REBs, which suggests that REBs may
not be fully in touch with potential consequences or impact of
innovations to patients. These findings are disturbing and
suggest that this is an area where best practice policies need
strengthening.
Innovation is a neglected area for ethics assessment.
Further studies on a larger scale are necessary to review the
concepts of experimental, innovative, and commonly accepted
care. Our findings appear to confirm Agich’sc o n c l u s i o n
(2001): we will need to pay closer attention to the actual
clinical, institutional, and professional processes that operate
in the development of novel therapeutic interventions. The
measures applied should also take account of the influence of
professional culture, whether clinical or scientific, in the
application of general definitions to a specific project.
Our pilot study looked at a particularly common type of
innovation, namely, that of a new biochemical test. There is a
need to further elaborate on the type of innovations in health
care and categorize the nature of the risks associated with
each. Further work could also look at why ethics committees
might show this large extent of variation. Further research
could have considerable implication for the education of both
REBs and health care professionals. The concern of the latter
is particularly interesting as it suggests that with appropriate
education there would be a greater awareness amongst
professionals of the risks linked to innovation and hence an
improved culture of risk avoidance in an area that is likely to
increase in complexity with biotechnological advance.
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